Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms

Histiocytic neoplasms are a heterogeneous group of clonal hematopoietic disorders marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway.(1,2) For the 50% of histiocytosis patients with BRAFV600-mutations(3–5), RAF inhibition is highly efficacious and has dramatically alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamond, Eli L., Durham, Benjamin H., Ulaner, Gary A, Drill, Esther, Buthorn, Justin, Ki, Michelle, Bitner, Lillian, Cho, Hana, Young, Robert J., Francis, Jasmine H, Rampal, Raajit, Lacouture, Mario, Brody, Lynn A., Ozkaya, Neval, Dogan, Ahmet, Rosen, Neal, Iasonos, Alexia, Abdel-Wahab, Omar, Hyman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/
https://www.ncbi.nlm.nih.gov/pubmed/30867592
http://dx.doi.org/10.1038/s41586-019-1012-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/
https://www.ncbi.nlm.nih.gov/pubmed/30867592
http://dx.doi.org/10.1038/s41586-019-1012-y

Ejemplares similares